CATALENT INC (CTLT)

US1488061029 - Common Stock

56.45  -0.03 (-0.05%)

After market: 56.5 +0.05 (+0.09%)

News Image
3 days ago - The Motley Fool

Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?

All three of these high-flying stocks could have more room to run.

News Image
7 days ago - Halper Sadeh LLP

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, HRT, NGM, SDPI

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image
10 days ago - The Motley Fool

Did Novo Nordisk Just Get a Jump on Eli Lilly?

A recent FDA announcement may have just put one company in the lead.

News Image
17 days ago - Halper Sadeh LLP

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, EVBG, ZFOX

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image
18 days ago - Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT). Such investors are...

News Image
20 days ago - InvestorPlace

The Top 3 Pharma Stocks to Buy in March2024

Investors explore the top three biotechnology stocks to buy in 2024 which are leading the anti-obesity market surge.

News Image
24 days ago - The Motley Fool

Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why

Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus.

News Image
a month ago - Kuehn Law, PLLC

Kuehn Law Encourages CHRD, AVRO, KAMN, and CTLT Investors to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...

News Image
a month ago - Halper Sadeh LLP

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates KAMN, CTLT, BATL

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image
a month ago - Halper Sadeh LLP

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates HRT, DOOR, CTLT, CALB

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image
a month ago - Halper Sadeh LLP

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, AXNX, BATL, APA

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image
a month ago - Pomerantz LLP

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Catalent, Inc. - CTLT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Catalent, Inc. ("Catalent" or the "Company") (NYSE: CTLT). Such investors are...

News Image
a month ago - Seeking Alpha

Catalent stock gains after filing 10-Q

Catalent experiences a 1% increase after filing its 10-Q late due to internal control matters, following its acquisition by Novo Holdings.

News Image
a month ago - Seeking Alpha

Catalent stock gains after filing 10-Q (NYSE:CTLT)

Catalent experiences a 1% increase after filing its 10-Q late due to internal control matters, following its acquisition by Novo Holdings.

News Image
2 months ago - The Motley Fool

Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?

Even more revenue is on the way from additional sales of Wegovy.

News Image
2 months ago - Seeking Alpha

Weight-loss drug market to lift “pick-and-shovel” plays

Nearly $4B opportunity awaits pick-and-shovel players in the booming weight loss drug market dominated by Novo Nordisk (NVO) and Eli Lilly (LLY). Read more here.

News Image
2 months ago - The Motley Fool

Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited

Novo Nordisk just made a unique acquisition to help bolster the supply of Wegovy and Ozempic.

News Image
2 months ago - Seeking Alpha

FTC likely to look at Catalent alternatives in review of Novo deal - report (NYSE:CTLT)

The Federal Trade Commission will review if drugmakers like Eli Lilly can find alternative suppliers in Novo Nordisk's purchase of Catalent and its plants.

News Image
2 months ago - Seeking Alpha

AstraZeneca looking to ramp up in-house production amid Catalent deal (NASDAQ:AZN)

AstraZeneca (AZN) is reportedly looking to reduce its reliance on contract manufacturers like Catalent (CTLT) by ramping up in-house production. Read more here.

News Image
2 months ago - Seeking Alpha

Catalent Non-GAAP EPS of -$0.24 misses by $0.22, revenue of $1.03B beats by $20M (NYSE:CTLT)

Catalent Inc. Q2 earnings report shows -$0.24 Non-GAAP EPS, missing estimates by $0.22.